Artiva Biotherapeutics (NASDAQ:ARTV) Earns Outperform Rating from Wedbush

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a note issued to investors on Tuesday,Benzinga reports. They presently have a $18.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 369.36% from the stock’s current price.

A number of other research analysts have also commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. HC Wainwright started coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They set a “buy” rating and a $20.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $20.40.

Artiva Biotherapeutics Price Performance

NASDAQ:ARTV traded down $0.08 during trading hours on Tuesday, hitting $3.84. 23,414 shares of the company traded hands, compared to its average volume of 113,040. Artiva Biotherapeutics has a twelve month low of $3.37 and a twelve month high of $17.31. The firm has a 50-day moving average of $4.97 and a 200 day moving average of $9.43.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ARTV. BNP Paribas Financial Markets bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $42,000. Charles Schwab Investment Management Inc. raised its stake in shares of Artiva Biotherapeutics by 8.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 43,526 shares of the company’s stock valued at $439,000 after acquiring an additional 3,233 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares in the last quarter. Northern Trust Corp grew its position in Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after acquiring an additional 4,335 shares during the last quarter. Finally, Barclays PLC increased its holdings in Artiva Biotherapeutics by 23.2% during the 4th quarter. Barclays PLC now owns 24,161 shares of the company’s stock valued at $244,000 after purchasing an additional 4,545 shares in the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.